Loading...
Loading...
Insmed Incorporated
, a biopharmaceutical company focused on developing and
commercializing inhaled therapies for patients battling serious lung
diseases in orphan indications that are often life-threatening, today
announced that ARIKACE(R) , the Company's Iiposomal amikacin for inhalation,
has received orphan drug designation from the U.S. Food and Drug
Administration (FDA) Office of Orphan Products Development for the treatment
of infections caused by non-tuberculous mycobacteria (NTM).
Orphan drug designation provides certain exclusivity benefits, tax credits
for certain research and a waiver of the New Drug Application user fee.
According to a recent company-sponsored patient chart study conducted by
Clarity Pharma Research, approximately 50,000 cases of NTM lung disease were
treated by physicians in the U.S. during 2011. There is no current
FDA-approved treatment for NTM lung infection.
"The FDA's timely approval of our request for orphan drug designation for
ARIKACE to treat non-tuberculous mycobacteria is a key milestone that
supports our broader strategy for this potentially life-saving therapy,"
stated Will Lewis, President and Chief Executive Officer of Insmed. "NTM is
a chronic, debilitating disease, and currently available treatments have
shown limited efficacy and tolerability. We continue to enroll patients in
our phase 2 clinical trial of ARIKACE to treat NTM patients in the U.S. and
Canada and look forward to having top-line data by the end of this year."
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in